BioInformant

Your Global Leader in Stem Cell Market Research

You are here: Home / Archives for Cell Therapy / CAR-T

Australian TGA Approves Novartis’ Kymriah® CAR-T Therapy for Two Blood Cancers

By

Kymriah® (tisagenlecleucel), CAR-T therapy from Novartis, receives TGA approval for treating two aggressive blood cancers

  • Kymriah® is an immunocellular therapy that is a one-time treatment manufactured individually for each patient using the patient’s own T cells, genetically reengineered and programmed to recognise and destroy cancer cells.
  • Kymriah® is approved for the treatment of relapsed or refractory patients with paediatric B-cell acute lymphoblastic leukaemia (ALL) and adult diffuse large B-cell lymphoma (DLBCL)[1]
  • Kymriah® could be a treatment option for about 50 paediatric and young adult ALL patients and 420 adult DLBCL patients who relapse or do not respond to initial therapy[2]
  • Kymriah® is the only chimeric antigen receptor T cell (CAR-T) therapy to receive TGA approval in Australia[1]

[Read more…]

CAR-T Companies: The Meteoric Rise Of Cellular Immunotherapies

By

Learn more about the leading CAR-T therapy companies and the technologies they use to fight cancer.

In this article:

    1. An Introduction to CAR-T Companies
    2. Chimeric Antigen Receptors
    3. Increase in CAR-T Biotech Companies
    4. Burgeoning Market for CAR-T Therapies
    5. A Swell of CAR-T Companies in 2018

Getting to Know the Leaders of the CAR-T Industry

 

An Introduction to CAR-T Companies

Chimeric antigen receptor T-cell therapy (CAR-T) is an approach that is now being explored as an alternative to conventional treatments for several forms of cancer. Thus, CAR-T companies are on the rise, supported by a growing investment flowing into CAR-T research, landmark approvals of CAR-T cell therapies by the U.S. FDA (Kymriah and Yescarta), and major acquisitions within the CAR-T space. Most notably, Celgene snagged Juno Therapeutics for a shocking $9 billion in January 2018, and Gilead acquired Kite Pharma for an astounding $11.9 billion in August 2017.  [Read more…]

Fate Therapeutics and ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies

By

Option-based Collaboration to Develop Two CAR T-Cell Product Candidates Using Fate’s Proprietary iPSC Product Platform

SAN DIEGO, Sept. 17, 2018 — Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has entered into a collaboration with ONO Pharmaceutical Co., Ltd. for the joint development and commercialization of two off-the-shelf CAR-T cell product candidates. Using Fate Therapeutics’ proprietary induced pluripotent stem cell (iPSC) product platform, the two CAR T-cell collaboration candidates will each be derived from a clonal master iPSC line engineered to completely eliminate endogenous TCR expression, insert a chimeric antigen receptor (CAR) into the TRAC locus and incorporate other anti-tumor functionality. [Read more…]

BioInformant's World-Class Clients